賽生藥業(06600.HK)受投資者熱捧,上限定價獲超額認購千倍
賽生藥業(06600.HK)香港IPO發行價取招股區間上限18.8港元,公吿顯示,根據國際發售提呈發售的股份獲大幅超額認購,相當於根據國際發售初步可供認購發售股份總數約【10】倍。根據香港公開發售初步提呈的香港發售股份獲大幅超額認購。合共接獲【436,000】份有效申請,認購合共【12,388,265,000】股,相當於根據香港公開發售初步可供認購香港發售股份總數約【1,068.05】倍,公司此次股票發行定價合理,受到市場追捧。
格隆匯據悉:該公司一家擁有產品和商業化集成平台的領先生物製藥公司,已上市產品銷售約20億元規模,並持續取得較快增長;在研產品競爭優勢突出,並處於熱門靶點,未來幾年內將接連落地。
根據公司招股書顯示,2017年至2019年公司營業收入分別為12.13億元、14.09億元、17.08億元,同比增長16.16%與21.22%。 2017年至2019年公司淨利潤分別為0.2億元、5.35億元、6.15億元,同比增長2575%以及14.95%。截至2020年9月30日,公司淨利潤為6.90億元,同比增長41.68%。
值得注意的是,在2020年疫情這一黑天鵝事件中,公司仍能夠呈現出營業收入與淨利潤兩者均高速增長的局面,良好的財務狀況體現了業務內核的強勁支撐。此外,此次上市定價合理,值得進一步關注後市發展。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.